Background: Family studies have served as a cornerstone of genetic research on colorectal cancer.

Materials and Methods: The Colorectal Cancer Family Registry (Colon CFR) is an international consortium of six centers in North America and Australia formed as a resource to support studies on the etiology, prevention, and clinical management of colorectal cancer. Differences in design and sampling schemes ensures a resource that covers the continuum of disease risk. Two separate recruitment strategies identified colorectal cancer cases: population-based (incident case probands identified by cancer registries; all six centers) and clinic-based (families with multiple cases of colorectal cancer presenting at cancer family clinics; three centers). At this time, the Colon CFR is in year 10 with the second phase of enrollment nearly complete. In phase I recruitment (1998-2002), population-based sampling ranged from all incident cases of colorectal cancer to a subsample based on age at diagnosis and/or family cancer history. During phase II (2002-2007), population-based recruitment targeted cases diagnosed before the age of 50 years are more likely attributable to genetic factors. Standardized protocols were used to collect information regarding family cancer history and colorectal cancer risk factors, and biospecimens were obtained to assess microsatellite instability (MSI) status, expression of mismatch repair proteins, and other molecular and genetic processes.

Results: Of the 8,369 case probands enrolled to date, 2,602 reported having one or more colorectal cancer–affected relatives and 799 met the Amsterdam I criteria for Lynch syndrome. A large number of affected (1,324) and unaffected (19,816) relatives were enrolled, as were population-based (4,108) and spouse (983) controls. To date, 91% of case probands provided blood (or, for a few, buccal cell) samples and 75% provided tumor tissue. For a selected sample of high-risk subjects, lymphocytes have been immortalized. Nearly 600 case probands had more than two affected colorectal cancer relatives, and 800 meeting the Amsterdam I criteria and 128, the Amsterdam II criteria. MSI testing for 10 markers was attempted on all obtained tumors. Of the 4,011 tumors collected in phase I that were successfully tested, 16% were MSI-high, 12% were MSI-low, and 72% were microsatellite stable. Tumor tissues from clinic-based cases were twice as likely as population-based cases to be MSI-high (34% versus 17%). Seventeen percent of phase I proband tumors and 24% of phase II proband tumors had some loss of mismatch repair protein, with the prevalence depending on sampling. Active follow-up to update personal and family histories, new neoplasms, and deaths in probands and relatives is nearly complete.

Conclusions: The Colon CFR supports an evolving research program that is broad and interdisciplinary. The greater scientific community has access to this large and well-characterized resource for studies of colorectal cancer. (Cancer Epidemiol Biomarkers Prev 2007;16(11):2331–43)

Family studies have served as a cornerstone of genetic research on colorectal cancer (1, 2). Studies of multiple-case families led to the discovery of the best characterized colorectal cancer susceptibility syndromes: hereditary nonpolyposis colorectal cancer (HNPCC; hereafter called Lynch syndrome; refs. 3, 4) and familial adenomatous polyposis (FAP; ref. 5). The primary genetic bases of these dominant, relatively high-penetrance syndromes were identified in kindreds as mutations in the DNA mismatch repair (MMR) genes for Lynch syndrome (6) and in components of the APC or Wnt signaling pathway for FAP (7-10). Somatic (11) and epigenetic (12, 13) alterations in these same genes are involved in sporadic colorectal cancer as well. Although mutations in the MMR and APC genes are established causes of colorectal cancer (14), many important questions remain, including (a) the population frequency of these mutations; (b) the molecular and pathologic characteristics, as well as family-history patterns, most strongly associated with these mutations; (c) the penetrance of these mutations by age and sex; and (d) the genetic and environmental risk factors that modify penetrance. Recognizing the importance of further characterizing these pathways and identifying additional susceptibility genes and environmental risk factors, as well as their joint effects, in colorectal cancer, the National Cancer Institute in 1997 funded the Cooperative Family Registry for Colorectal Cancer Studies, which was competitively renewed in 2002 as the Colorectal Cancer Family Registry (Colon CFR). The Colon CFR joins the Breast Cancer Family Registry (15) as a research infrastructure for investigators interested in conducting population-based and clinic-based studies of the genetic and molecular epidemiology of these two common cancers.

The Colon CFR was developed by a multidisciplinary team of international investigators as a consortium of six field centers and an informatics support center (ISC). The participating centers are Cancer Care Ontario (CCO), Fred Hutchinson Cancer Research Center (FHCRC), Mayo Clinic, University of Hawaii (UHI), University of Southern California (USC), University of Melbourne (Australasia). The ISC developed a central database with limited data sets from all the participating centers. By the end of the second grant cycle of the Colon CFR in 2007, data and biospecimens would have been collected from nearly 10,000 probands and nearly 27,000 selected affected and unaffected relatives and controls. To facilitate the use of this resource by the scientific community, we describe the design and methods of the Colon CFR and the baseline data on colorectal cancer cases, their families, and controls, and provide a brief overview of the research and plans to date.

Overview

The Colon CFR is mandated to build and maintain a registry of high-risk colorectal cancer patients and families; collect detailed personal and family histories, including epidemiologic risk factors; obtain biological specimens; and conduct follow-up of the participants for colorectal neoplasia and other outcomes. The goal is to stimulate a broad cooperative effort based on this resource. After peer review of applications in 1997, six research institutions were selected from the United States, Canada, and Australia. Case ascertainment pools were derived from both cancer registries (population-based families) and cancer family clinics (clinic-based families). For phase I (1997-2002) center-specific ascertainment schemes further focused recruitment on families at increased risk for colorectal cancer based on age at onset and/or family history. Expansion of the Colon CFR continued in phase II (2002-2007), with new recruitment and data collection (phase II enrollees), follow-up data collection, and substantial molecular characterization of all phase I proband and family member enrollees. The infrastructure and progress are described below, and details can be found at http://epi.grants.cancer.gov/CFR/about_colon.html.

Structure

The participating centers are supported by the National Cancer Institute through the Cooperative Agreement grant mechanism. The investigators of the Colon CFR comprise a multidisciplinary team of epidemiologists, molecular biologists, medical and surgical clinicians, geneticists, pathologists, biostatisticians, and behavioral scientists. A steering committee is responsible for developing and applying Colon CFR–wide policies and procedures, setting research agendas, monitoring study progress, reviewing research proposals, addressing operational problems, and resolving intraconsortium issues. Voting members of the Steering Committee are defined as the principal investigator and one coinvestigator from each of the six research institutions and the ISC, one community representative, one elected nonaffiliated research scientist with expertise in multidisciplinary and translational colorectal cancer research, and the National Cancer Institute project officer. The Steering Committee has established several working groups that coordinate the work of the Colon CFR. These working groups include Epidemiology and Analysis; Biospecimens and Microsatellite Instability (MSI); Molecular Characterization and Pathology; Access and Tracking; Diet; Prevention Trials; Treatment and Outcomes; Behavioral and Education; and Technical. These groups have produced the protocols and procedures used at each site and collaborate closely with the ISC to assure the timely and accurate transmission of data. The Advisory Committee provides external oversight of the research agenda and reviews specific applications to use consortium resources. Additionally, the ISC manages the storage, archiving, and dissemination of deidentified data from each of the Colon CFR centers. In collaboration with the Colon CFR investigators and working groups, the ISC has developed and implemented a comprehensive system for processing, storing, and retrieving core data. Using secure FTP for transfers, the centers upload the data files according to regular schedules. The ISC has worked closely with the Colon CFR investigators and working groups to define quality control procedures. The ISC runs extensive computer edits on transmitted data and posts any resulting edit discrepancies to a secure Web site. The ISC has developed additional core software systems and assembles data sets for approved investigator requests (Fig. 1).

Figure 1.

Colon CFR infrastructure.

Figure 1.

Colon CFR infrastructure.

Close modal

Ascertainment and Recruitment

The Colon CFR includes six study centers that have used varying designs and sampling schemes to recruit families (Table 1). This diversity is a primary strength, as it offers standardized data relevant to populations that differ in their underlying genetic and environmental risk profiles. The same questionnaires and biospecimen protocols have been used for all families so that data can be combined to address numerous research questions, if necessary, using a proband weighting system (described briefly below) and selection of comparison groups, if appropriate.

Table 1.

CFR eligibility specifications by center

Population-based recruitment
CFR site/ascertainment sourcePhase I (1997-2002)Phase II (2002-2007)
UHI/SEER Registry for State of Hawaii • Diagnosed in the state of Hawaii between 1997 and 2001 with adenocarcinoma of colon/rectum. • Diagnosed in the state of Hawaii between 2002 and 2006 with adenocarcinoma of colon/rectum before the age of 50 y. All living FDRs and spouse of all colorectal cancer–affected participants are recruited. 
 • 100% cases in multiple-case families (i.e., with 1+ FDR with colorectal cancer). Parents and siblings of probands, children and spouses of affected family members, and children and spouses of affected family members and SDRs in families with three or more affected family members were recruited. • Japanese Americans diagnosed in the state of Hawaii between 2002 and 2006 with adenocarcinoma of colon/rectum between the age of 18 and 74 y. In multiple-case families, living parents, affected siblings, and one unaffected sibling are recruited along with the FDRs and spouse of all additional colorectal cancer–affected family members. 
 • 0% single-case families were recruited.  
Mayo Clinic/Minnesota Cancer Surveillance System (split 50:50 with USC) • Diagnosed in the state of Minnesota between 1997 and 2000 with colorectal cancer between the ages of 18 and 74 y. • Diagnosed with colorectal cancer in the state of Minnesota between 2002 and 2007. 
 • 100% cases in multiple living-case families (case has ≥1 living colorectal cancer–affected family members). • 100% cases diagnosed under the age of 50 y (no family history eligibility criteria) 
 • 100% cases diagnosed under the age of 50 y (no family history eligibility criteria). • 100% cases diagnosed between the ages of 51 and 74 y in multiple-case families (must have ≥3 colorectal cancer–affected cases, at least two of which are living and at least two are FDR degree or a living colorectal cancer–affected sibling-pair). 
 • 33% random sample of all cases until 200 total probands ascertained in this way have been recruited.  
FHCRC/Puget Sound SEER • Diagnosed in Washington's King, Snohomish, or Pierce Counties between January 1998 and June 2002 with incident colorectal cancer between the ages of 20 and 74 y. • Diagnosed in 1 of the 13 Western Washington SEER counties (containing 73% of the state's population) between April 2002 and July 2007 with incident colorectal cancer between the ages of 18 and 49 y. 
 • 100% cases (no family history eligibility criteria). All colorectal cancer–affected FDRs were recruited. All living FDRs (affected and unaffected) in families with three or more cases of colorectal cancer were recruited. All unaffected FDRs in ∼50% of families with less than three cases of colorectal cancer were recruited. • 100% cases (no family history eligibility criteria). 
USC Consortium/LA County Cancer Surveillance Program Cancer Registries in Arizona, Colorado, Minnesota (split 50:50 with Mayo Clinic), New Hampshire, University of North Carolina • Diagnosed in either LA County, Arizona, Colorado, Minnesota, and New Hampshire states or one of the 33 North Carolina counties between 1997(1996 CO) and 1999 with colorectal cancer between the ages of 21 and 75 y. LA County Cancer Surveillance Program Cancer Registries: African American or Japanese American cases diagnosed in LA County between 2002 and 2006 with colorectal cancer between the age of 21 and 75 y. 
 • Screened: 33% Whites, >50 y; 66% Whites, <50 y; 66% all minorities, 21-75 y. • 100% of cases in families with <3 cases of colorectal cancer (no family history eligibility criteria) and selected FDRs are recruited. 
 • Recruited: of cases screened, 100% of multiple-case and 16% of single-case families and selected colorectal cancer–affected and unaffected family members (to third degree) were recruited. • 100% of cases in families with ≥3 cases of colorectal cancer and selected family members (to third degree) are recruited. 
  University of North Carolina: African-American cases diagnosed in 1 of 38 Carolina counties between 2002 and 2006 with colorectal cancer between the age of 21 and 75 y. 
  • 100% of cases in families with <3 cases of colorectal cancer (no family history eligibility criteria) and selected FDRs are recruited. 
  • 100% of cases in families with ≥3 cases of colorectal cancer and selected family members (to third degree) are recruited. 
  •100% of cases in families with ≥3 cases of colorectal cancer and selected family members (to third degree) are recruited. 
  ASCR, CSCR, MSCC, NHCR: Diagnosed in Arizona, Colorado, Minnesota, or New Hampshire between 2002 and 2006 with colorectal cancer between the age of 21 and 50 y. 
  •100% cases and all FDRs are recruited. 
Australasia/Victorian Cancer Registry •Diagnosed in Melbourne between 1997 and 2001 with first primary adenocarcinoma of colon/rectum between ages of 18 and 59 y. •Diagnosed in Melbourne between 2001 and 2006 with first primary adenocarcinoma of colon/rectum between the ages of 18 and 49 y. 
 •100% of cases ages 18 to 44 at diagnosis, all FDRs and SDRs of the case, and all FDRs of additional colorectal cancer–affected family members were recruited. •100% of cases (no family history eligibility criteria), all FDRs and SDRs of the case, and all FDRs of additional colorectal cancer–affected family members are recruited. 
 •50% of cases ages 45 to 59 y (no family history eligibility criteria), all FDRs and SDRs of the case, and all FDRs of additional colorectal cancer–affected family members were recruited.  
Cancer Care Ontario/Ontario Cancer Registry •Diagnosed in Ontario between July 1997 and June 2000 with incident colorectal cancer between the ages of 20 and 74 y (from 7/1/97 to 3/13/99) and between 20 and 69 y (after 3/15/99). •Diagnosed in the province of Ontario between January 2003 and December 2006 with incident colorectal cancer under the age 50 y. 
 •100% of cases in Amsterdam-I* and intermediate-risk families and their FDR, half-siblings on the at-risk side, and blood relatives with an HNPCC cancer on the at-risk side were recruited. •100% cases and all FDRs, half-siblings on at-risk side (if no risk side than all half sibs), all SDRs on at-risk side only (include adult FDR if HNPCC is affected), and all other blood relative with HNPCC on at-risk side with their living adult FDR relatives are recruited. 
 •100% cases in multiple-case families (proband + with 2+ FDR or SDR <36 y with an HNPCC or other cancer) and all FDRs, half-siblings on at-risk side, and blood relatives with HNPCC on at-risk side with their adult FDR >17 y were recruited. •All cases with FAP are excluded. 
 •25% cases in single-case families, and for 25% of these cases, all FDR, half siblings, and blood relatives with HNPCC with their adult FDR >17 y were recruited.  
 •All cases with FAP were excluded.  
Population-based recruitment
CFR site/ascertainment sourcePhase I (1997-2002)Phase II (2002-2007)
UHI/SEER Registry for State of Hawaii • Diagnosed in the state of Hawaii between 1997 and 2001 with adenocarcinoma of colon/rectum. • Diagnosed in the state of Hawaii between 2002 and 2006 with adenocarcinoma of colon/rectum before the age of 50 y. All living FDRs and spouse of all colorectal cancer–affected participants are recruited. 
 • 100% cases in multiple-case families (i.e., with 1+ FDR with colorectal cancer). Parents and siblings of probands, children and spouses of affected family members, and children and spouses of affected family members and SDRs in families with three or more affected family members were recruited. • Japanese Americans diagnosed in the state of Hawaii between 2002 and 2006 with adenocarcinoma of colon/rectum between the age of 18 and 74 y. In multiple-case families, living parents, affected siblings, and one unaffected sibling are recruited along with the FDRs and spouse of all additional colorectal cancer–affected family members. 
 • 0% single-case families were recruited.  
Mayo Clinic/Minnesota Cancer Surveillance System (split 50:50 with USC) • Diagnosed in the state of Minnesota between 1997 and 2000 with colorectal cancer between the ages of 18 and 74 y. • Diagnosed with colorectal cancer in the state of Minnesota between 2002 and 2007. 
 • 100% cases in multiple living-case families (case has ≥1 living colorectal cancer–affected family members). • 100% cases diagnosed under the age of 50 y (no family history eligibility criteria) 
 • 100% cases diagnosed under the age of 50 y (no family history eligibility criteria). • 100% cases diagnosed between the ages of 51 and 74 y in multiple-case families (must have ≥3 colorectal cancer–affected cases, at least two of which are living and at least two are FDR degree or a living colorectal cancer–affected sibling-pair). 
 • 33% random sample of all cases until 200 total probands ascertained in this way have been recruited.  
FHCRC/Puget Sound SEER • Diagnosed in Washington's King, Snohomish, or Pierce Counties between January 1998 and June 2002 with incident colorectal cancer between the ages of 20 and 74 y. • Diagnosed in 1 of the 13 Western Washington SEER counties (containing 73% of the state's population) between April 2002 and July 2007 with incident colorectal cancer between the ages of 18 and 49 y. 
 • 100% cases (no family history eligibility criteria). All colorectal cancer–affected FDRs were recruited. All living FDRs (affected and unaffected) in families with three or more cases of colorectal cancer were recruited. All unaffected FDRs in ∼50% of families with less than three cases of colorectal cancer were recruited. • 100% cases (no family history eligibility criteria). 
USC Consortium/LA County Cancer Surveillance Program Cancer Registries in Arizona, Colorado, Minnesota (split 50:50 with Mayo Clinic), New Hampshire, University of North Carolina • Diagnosed in either LA County, Arizona, Colorado, Minnesota, and New Hampshire states or one of the 33 North Carolina counties between 1997(1996 CO) and 1999 with colorectal cancer between the ages of 21 and 75 y. LA County Cancer Surveillance Program Cancer Registries: African American or Japanese American cases diagnosed in LA County between 2002 and 2006 with colorectal cancer between the age of 21 and 75 y. 
 • Screened: 33% Whites, >50 y; 66% Whites, <50 y; 66% all minorities, 21-75 y. • 100% of cases in families with <3 cases of colorectal cancer (no family history eligibility criteria) and selected FDRs are recruited. 
 • Recruited: of cases screened, 100% of multiple-case and 16% of single-case families and selected colorectal cancer–affected and unaffected family members (to third degree) were recruited. • 100% of cases in families with ≥3 cases of colorectal cancer and selected family members (to third degree) are recruited. 
  University of North Carolina: African-American cases diagnosed in 1 of 38 Carolina counties between 2002 and 2006 with colorectal cancer between the age of 21 and 75 y. 
  • 100% of cases in families with <3 cases of colorectal cancer (no family history eligibility criteria) and selected FDRs are recruited. 
  • 100% of cases in families with ≥3 cases of colorectal cancer and selected family members (to third degree) are recruited. 
  •100% of cases in families with ≥3 cases of colorectal cancer and selected family members (to third degree) are recruited. 
  ASCR, CSCR, MSCC, NHCR: Diagnosed in Arizona, Colorado, Minnesota, or New Hampshire between 2002 and 2006 with colorectal cancer between the age of 21 and 50 y. 
  •100% cases and all FDRs are recruited. 
Australasia/Victorian Cancer Registry •Diagnosed in Melbourne between 1997 and 2001 with first primary adenocarcinoma of colon/rectum between ages of 18 and 59 y. •Diagnosed in Melbourne between 2001 and 2006 with first primary adenocarcinoma of colon/rectum between the ages of 18 and 49 y. 
 •100% of cases ages 18 to 44 at diagnosis, all FDRs and SDRs of the case, and all FDRs of additional colorectal cancer–affected family members were recruited. •100% of cases (no family history eligibility criteria), all FDRs and SDRs of the case, and all FDRs of additional colorectal cancer–affected family members are recruited. 
 •50% of cases ages 45 to 59 y (no family history eligibility criteria), all FDRs and SDRs of the case, and all FDRs of additional colorectal cancer–affected family members were recruited.  
Cancer Care Ontario/Ontario Cancer Registry •Diagnosed in Ontario between July 1997 and June 2000 with incident colorectal cancer between the ages of 20 and 74 y (from 7/1/97 to 3/13/99) and between 20 and 69 y (after 3/15/99). •Diagnosed in the province of Ontario between January 2003 and December 2006 with incident colorectal cancer under the age 50 y. 
 •100% of cases in Amsterdam-I* and intermediate-risk families and their FDR, half-siblings on the at-risk side, and blood relatives with an HNPCC cancer on the at-risk side were recruited. •100% cases and all FDRs, half-siblings on at-risk side (if no risk side than all half sibs), all SDRs on at-risk side only (include adult FDR if HNPCC is affected), and all other blood relative with HNPCC on at-risk side with their living adult FDR relatives are recruited. 
 •100% cases in multiple-case families (proband + with 2+ FDR or SDR <36 y with an HNPCC or other cancer) and all FDRs, half-siblings on at-risk side, and blood relatives with HNPCC on at-risk side with their adult FDR >17 y were recruited. •All cases with FAP are excluded. 
 •25% cases in single-case families, and for 25% of these cases, all FDR, half siblings, and blood relatives with HNPCC with their adult FDR >17 y were recruited.  
 •All cases with FAP were excluded.  

NOTE: Intermediate risk families were defined as proband + 2 relatives (first- or second-degree relatives only) with **HNPCC or other cancer or one relative (first- or second-degree relatives) <36 with **HNPCC or other cancer or proband <50 + 1 relative (first- or second-degree relatives) with colorectal cancer <50, or proband <36 y, or proband with multiple **HNPCC or other cancer, or proband with >4 multiple adenomatous or hyperplastic polyp or proband with inflammatory bowel disease (Crohn's or ulcerative colitis) or proband with Ashkenazi Jewish ancestry.

Abbreviations: FDR, first-degree relatives; SDR, second-degree relatives.

*

Amsterdam 1: At least three family members with colorectal cancer, and one is a first-degree relative of the other two and two consecutive generations are represented, and at least one individual is younger than 50 y at diagnosis, and FAP is excluded.

HNPCC or other cancers: colorectal cancer, endometrium, stomach, small bowel, gastroesophageal region, pancreas, biliary duct, liver, ovary, kidney, ureter, brain and lymphoma (and for phase II: sebaceous adenoma/adenocarcinoma, and keratoacanthoma).

In general, two recruitment strategies have been used: population-based and clinic-based. Phase I recruitment began in 1997 and was completed in July 2002. Phase II recruitment continues with centers targeting certain subgroups for recruitment, including (a) families with possible MMR mutations, including those cases with incident colorectal cancer diagnosed under the age of 50 years (all centers) and/or families with multiple cases of colorectal cancer (Mayo Clinic) or (b) families from specific racial and ethnic groups. Enhanced recruitment of Japanese Americans (UHI) and African Americans (USC) is funded under a separate grant.

Phase I Population-Based Recruitment (1997-2002). All six Colon CFR centers enrolled families with incident colorectal cancer identified through population-based cancer registries in defined geographic areas. Sampling probabilities differed according to age at diagnosis, race, and/or family history of colorectal cancer, depending on center. Sampling schemes ranged from inviting all eligible cases to participate (FHCRC) to a single-stage design in which all early-onset and a fraction of older-onset cases were recruited, irrespective of family history, sex, or any other factor (Australasia), to a two-stage stratified sampling design in which race/ethnicity and/or age at diagnosis were used to select case probands to approach for family history data collection and the resulting family history information to select probands for enrollment (UHI, Mayo Clinic, CCO, USC). Table 1 describes recruitment for population-based centers. At all centers except Australasia, all case probands reporting a first-degree family history of colorectal cancer were eligible and recruited. In Australasia, sampling fractions were based on age at diagnosis, not family history. After enrollment of the case proband, his/her permission and assistance was sought to contact eligible and available relatives. The selection of family members for recruitment was center-specific, ranging from first-degree only to the inclusion of second- and third-degree relatives.

Because of these differing sampling schemes, for some analyses it may be necessary to use proband weights. These weights are defined as the inverse of the probability that a case proband was selected for recruitment. For example, for the two-stage designs, the overall sampling probability is the product of the stage 1 and stage 2 sampling probabilities. For FHCRC, where all case probands of eligible age were eligible, all case probands receive a sampling probability of 1. The UHI contributed only family history–positive cases, thus proband weights by family history are not definable and data from this center are most suitable for analyses limited to familial forms of colorectal cancer. Proband weights have been calculated for all population-based families in the Colon CFR and have been transmitted to the ISC. Weights are available to users through the ISC.

During Phase I, controls were either randomly sampled from the general population living in the relevant recruitment area using Medicare and Driver's License files (FHCRC), telephone subscribers lists (CCO), or electoral rolls (Australasia), or were ascertained through the case proband, either as the spouse (UHI, Australasia, and Mayo Clinic) or as an unaffected family member (USC).

Phase I Clinic-Based Recruitment. Three centers also recruited families with multiple or early-onset cases of colorectal cancer through clinical settings: Mayo Clinic, USC (Cleveland Clinic subcenter), and Australasia (seven family cancer clinics across Australia and New Zealand). Clinic-based probands, defined as the first family member enrolled in the Colon CFR registry, may or may not have had a personal history of colorectal cancer. Instead, eligibility was based on one or more of the following criteria: two or more relatives with a personal history of colorectal cancer or Lynch syndrome cancer, a proband diagnosed with colorectal cancer at a young age, or a proband presenting at a clinic with Lynch syndrome or Lynch-like syndrome. After proband enrollment, permission and assistance were sought to contact eligible and available relatives. Control participants were also ascertained through the proband: spouse (Mayo Clinic, Australasia) or unaffected family member (USC). Table 2 provides an overview of the sampling strategies for the clinic-based families.

Table 2.

CFR eligibility specifications by center

Clinic-based recruitment
CFR site/ascertainment sourcePhase I (1997-2002)Phase II (2002-2007)
Mayo Clinic/Mayo Clinic Rochester; North Central Cancer Treatment Group • Presented to clinic between 1997 and 2000 with colorectal cancer between the ages of 18 and 74 y. • Presented with colorectal cancer at age 18 to 74 y between 1997 and 2000. 
 • 100% cases in multiple living-case families (case has one or more living colorectal cancer–affected family member) were recruited. • 100% cases in multiple living-case families (case has one or more living colorectal cancer–affected family members). 
 • 100% cases <50 y at diagnosis were recruited. • 100% cases <50 y at diagnosis. 
 • 0% cases in single-case families (unless diagnosed <50) • 0% cases in single-case families (unless diagnosed <50). 
USC Consortium/Cleveland Clinic Colorectal Cancer Registry • Presented to clinic with an HNPCC or HNPCC-like history (three colorectal cancer, or two colorectal cancer and one uterine, or two colorectal cancer plus polyps (one tubular villous/villous adenoma, or one 1-cm adenoma, or ≥3 adenomas), one is <50 y, and one is FDR of the other two, and are in successive generations). • Presented to clinic with an HNPCC or HNPCC-like history [three colorectal cancer, or two colorectal cancer and one uterine, or two colorectal cancer, plus polyps (one tubular villous/villous adenoma, or one 1-cm adenoma, or ≥3 adenomas), one is <50 y and one is FDR of the other two in successive generations]. 
 • Proband (first member of the family to contact clinic — may or not be affected) ages 21 to 75 y at presentation. • Proband (first member of the family to contact clinic — may or not be affected) ages 21 to 75 y at presentation. 
 • All colorectal cancer–affected family members and selected unaffected family members (to third degree) were recruited. • All colorectal cancer–affected family members and selected unaffected family members (to third degree) were recruited. 
Australasia/Clinics (Brisbane, Melbourne, Adelaide, Sydney, Perth, Auckland New Zealand) • Presented to a clinic with a family history of colorectal cancer or a surrogate cancer (adenoma of colorectum, endometrial, gastric, small intestinal, urinary tract, central nervous system) or with a strong family history of HNPCC (probands may be unaffected with colorectal cancer). • Presented with a family history of colorectal cancer or surrogate cancer. 
 • All FDRs and SDRs, along with additional affected relatives (with colorectal cancer or related cancers) were recruited. • Any family with a known mutation has a pathogenic germline mutation in a MMR gene and has ≥1 living carrier or ≥2 living FDRs of a known carrier. All known living carriers, their FDRs, and all other living blood relatives of known carriers reporting a previous cancer diagnosis are recruited. 
  • Any family meeting the Amsterdam I or II criteria, and in which a CR tumor has been identified that is (a) MSI-high or absent for any mismatch repair protein and (b) has ≥1 living colorectal cancer–affected FDR. 
  • All living individuals with a colorectal cancer or EC tumor that is MSI-high or is absent for a MMR gene protein (probable carriers). All living blood relatives of probable carriers reporting a previous cancer diagnosis and all living FDRs of probable carriers are recruited. 
Ontario N/A To recruit 100 families with following characteristics: 
  • Amsterdam I (three or more members with olorectal cancer, one is FDR of other two and in two consecutive generations and at least one individual is <50 y and FAP is excluded). 
  • Amsterdam II criteria (at least three family members affected with any of these cancers: colorectal cancer, EC, ureter, kidney (transitional cell only), small intestine, sebaceous adenoma or keratoacanthoma, one is FDR of other two and in two consecutive generations and at least one individual is younger than 50 y and FAP is excluded). 
  •Amsterdam II criteria (at least three family members affected with any of these cancers: colorectal cancer, EC, ureter, kidney (transitional cell only), small intestine, sebaceous adenoma or keratoacanthoma, one is FDR of other two and in two consecutive generations and at least one individual is younger than 50 y and FAP is excluded). 
  •Proband is the first affected person presenting to the clinic and alive at the time of phase II recruitment OR his/her first-degree relative (if the affected proband has died). 
  •Has a MMR mutation identified in a family that does not meet Amsterdam I or II criteria 
  •Diagnosis age is >49 y and has fresh frozen tumor banked at biospecimen repository at Mount Sinai Hospital Toronto. 
  •All FDR + half-siblings on at-risk side (if no risk side than all half sibs), all SDRs on at-risk side only (include adult FDR if HNPCC affected), and other blood relative with HNPCC on at-risk side with their adult FDR-only live relatives >17 y meeting. 
Clinic-based recruitment
CFR site/ascertainment sourcePhase I (1997-2002)Phase II (2002-2007)
Mayo Clinic/Mayo Clinic Rochester; North Central Cancer Treatment Group • Presented to clinic between 1997 and 2000 with colorectal cancer between the ages of 18 and 74 y. • Presented with colorectal cancer at age 18 to 74 y between 1997 and 2000. 
 • 100% cases in multiple living-case families (case has one or more living colorectal cancer–affected family member) were recruited. • 100% cases in multiple living-case families (case has one or more living colorectal cancer–affected family members). 
 • 100% cases <50 y at diagnosis were recruited. • 100% cases <50 y at diagnosis. 
 • 0% cases in single-case families (unless diagnosed <50) • 0% cases in single-case families (unless diagnosed <50). 
USC Consortium/Cleveland Clinic Colorectal Cancer Registry • Presented to clinic with an HNPCC or HNPCC-like history (three colorectal cancer, or two colorectal cancer and one uterine, or two colorectal cancer plus polyps (one tubular villous/villous adenoma, or one 1-cm adenoma, or ≥3 adenomas), one is <50 y, and one is FDR of the other two, and are in successive generations). • Presented to clinic with an HNPCC or HNPCC-like history [three colorectal cancer, or two colorectal cancer and one uterine, or two colorectal cancer, plus polyps (one tubular villous/villous adenoma, or one 1-cm adenoma, or ≥3 adenomas), one is <50 y and one is FDR of the other two in successive generations]. 
 • Proband (first member of the family to contact clinic — may or not be affected) ages 21 to 75 y at presentation. • Proband (first member of the family to contact clinic — may or not be affected) ages 21 to 75 y at presentation. 
 • All colorectal cancer–affected family members and selected unaffected family members (to third degree) were recruited. • All colorectal cancer–affected family members and selected unaffected family members (to third degree) were recruited. 
Australasia/Clinics (Brisbane, Melbourne, Adelaide, Sydney, Perth, Auckland New Zealand) • Presented to a clinic with a family history of colorectal cancer or a surrogate cancer (adenoma of colorectum, endometrial, gastric, small intestinal, urinary tract, central nervous system) or with a strong family history of HNPCC (probands may be unaffected with colorectal cancer). • Presented with a family history of colorectal cancer or surrogate cancer. 
 • All FDRs and SDRs, along with additional affected relatives (with colorectal cancer or related cancers) were recruited. • Any family with a known mutation has a pathogenic germline mutation in a MMR gene and has ≥1 living carrier or ≥2 living FDRs of a known carrier. All known living carriers, their FDRs, and all other living blood relatives of known carriers reporting a previous cancer diagnosis are recruited. 
  • Any family meeting the Amsterdam I or II criteria, and in which a CR tumor has been identified that is (a) MSI-high or absent for any mismatch repair protein and (b) has ≥1 living colorectal cancer–affected FDR. 
  • All living individuals with a colorectal cancer or EC tumor that is MSI-high or is absent for a MMR gene protein (probable carriers). All living blood relatives of probable carriers reporting a previous cancer diagnosis and all living FDRs of probable carriers are recruited. 
Ontario N/A To recruit 100 families with following characteristics: 
  • Amsterdam I (three or more members with olorectal cancer, one is FDR of other two and in two consecutive generations and at least one individual is <50 y and FAP is excluded). 
  • Amsterdam II criteria (at least three family members affected with any of these cancers: colorectal cancer, EC, ureter, kidney (transitional cell only), small intestine, sebaceous adenoma or keratoacanthoma, one is FDR of other two and in two consecutive generations and at least one individual is younger than 50 y and FAP is excluded). 
  •Amsterdam II criteria (at least three family members affected with any of these cancers: colorectal cancer, EC, ureter, kidney (transitional cell only), small intestine, sebaceous adenoma or keratoacanthoma, one is FDR of other two and in two consecutive generations and at least one individual is younger than 50 y and FAP is excluded). 
  •Proband is the first affected person presenting to the clinic and alive at the time of phase II recruitment OR his/her first-degree relative (if the affected proband has died). 
  •Has a MMR mutation identified in a family that does not meet Amsterdam I or II criteria 
  •Diagnosis age is >49 y and has fresh frozen tumor banked at biospecimen repository at Mount Sinai Hospital Toronto. 
  •All FDR + half-siblings on at-risk side (if no risk side than all half sibs), all SDRs on at-risk side only (include adult FDR if HNPCC affected), and other blood relative with HNPCC on at-risk side with their adult FDR-only live relatives >17 y meeting. 

Abbreviation: N/A, not available.

Phase II Recruitment (2002-2007). To increase the sample size of MMR carriers and examine genetic and environmental risk factors for known, as well as yet unknown, genetic syndromes, recruitment was expanded to (a) more recently diagnosed population-based incident probands diagnosed under the age of 50 years and their first degree relatives and (b) more clinic-based families presenting at cancer family clinics (Table 2). The Colon CFR is also enhancing its minority component by recruiting additional Japanese Americans and African Americans, two groups in the United States whose colorectal cancer risk varies from that of the White population. Population-based controls continued to be recruited during phase II at FHCRC.

Protocols and Procedures

The Colon CFR centers all use standardized core protocols and instruments for personal and family history data, biospecimens collection, laboratory analysis, and data transmission and summaries. These materals were developed by the relevant working groups; questionnaires and protocols are described in detail at http://epi.grants.cancer.gov/CFR/index.html.

Core Questionnaire. Family history and personal exposures (except diet; see below) have been consistently collected at all sites to facilitate joint analyses. Each selected proband, population-based and spouse controls, completed the family history questionnaire either in person (USC), by telephone (FHCRC, USC, Australasia), or by mail (UHI, CCO, Mayo Clinic). The questionnaire acquired information on the number, sex, and birthdates of first-degree relatives (parents, siblings, and children), their cancer history, vital status, and, if deceased, date of death. All cancers, except for nonmelanoma skin cancers, were recorded with dates of diagnoses. Pedigrees were expanded to second- and third-degree relatives in several centers, depending on center-specific protocols and the reported family history.

Depending on the sampling schema, subjects also completed the epidemiologic questionnaire that captures information on established and suspected risk factors for colorectal cancer, including medical history and medication use, reproductive history (for female participants), physical activity, demographics, alcohol and tobacco use, race and ethnicity, and limited dietary data. The questionnaire was given to selected Colon CFR participants, including cases, controls, and affected and unaffected relatives, and defines a participant as an enrollee. Australasia and the UHI also used a short proxy version to collect limited information on selected individuals who were deceased, unavailable, or unwilling to participate. Centers customized questions for local usage, in particular for different language conventions and brand names, and were allowed to add additional questions of local interest. Detailed question-by-question manuals for administration were developed for further standardization.

Dietary Questionnaire. Diet is important in the genesis of colorectal cancer. Four Colon CFR centers collected dietary information using a self-administered diet history questionnaire from enrollees (cases, controls, and family members). The diet history questionnaire developed at UHI for use by the Multiethnic Cohort study in Hawaii and California was used at UHI, CCO, and USC (16). Australasian centers used a locally validated dietary questionnaire developed for a cohort study of >40,000 Greek, Italian, and Australian-born citizens of Melbourne (17). Both instruments collected information on the frequency of food consumption and portion size.

Biospecimens. For hypothesis-driven research to be based on this resource, extensive characterization of the families in the resource and of their cancers was required. Biospecimens (blood and paraffin-embedded tumor tissue) were obtained from cases and selected relatives and controls according to established Colon CFR protocols. Initial processing included blood sample separation and aliquoting (or tissue sectioning) and storage.

Blood or Buccal Cell Collection. A standardized protocol was used to collect and process blood samples. In general, blood was collected in EDTA and/or ACD (or heparin) vacutainer tubes. From these blood samples, whole blood spots were prepared on Schleicher and Schuel specimen collection paper (“Guthrie cards”), dried, and stored at room temperature; plasma and buffy coat (or other WBC component) were isolated, aliquoted, and stored; viable lymphocyte cells were separated by Ficoll separation procedure, aliquoted, slow-frozen, and stored in liquid nitrogen for eventual EBV-transformation to a lymphoblastoid cell line.

For subjects who did not consent to a blood draw, some centers sought a buccal cell sample. To ensure the highest possible DNA yield and quality, we used the specimen collection and processing protocol based on the mouthwash protocol of Lum and Le Marchand (18). The mailed kit contained an informed consent document, detailed instructions, and all materials needed for producing the sample and returning it to the study center. In general, the acceptability of this protocol and the quality of DNA has been high (19).

To facilitate collaborative research on colorectal cancer, a supplementary award was obtained that enabled all centers to extract germline DNA from blood or mouthwash samples for all phase I samples. Colon CFR–wide quality control studies on a sample of DNA specimens, including checking DNA concentration, absorbance ratio (260/280), DNA fragment size, and PCR amplification at six microsatellite loci were done by Coriell Institute for Medical Research.

EBV Transformation. To provide an unlimited supply of this valuable DNA, as well as RNA, supplementary funds were obtained to transform and maintain lymphoblastoid cell lines using EBV (20) on selected phase I participants. Using standard protocols, immortalization and subsequent DNA extractions were done at four laboratories: Coriell Institute for Medical Research, Mayo Clinic, University of Queensland, and Hospital for Sick Children in Toronto. The selection of samples for transformation was based on the proband's risk status: probands from families with two or more cases of colorectal cancer and probands diagnosed with colorectal cancer under the age of 50 years had the highest priority. To date, ∼4,100 specimens have been EBV-transformed.

Pathology Materials. Paraffin-embedded colorectal tumors and diagnostic pathology reports from colorectal cancer–affected probands and relatives were obtained from treating institutions, following informed consent. A standardized protocol to select and section representative blocks was developed by the Pathology working group. In general, sections were cut from each tumor and normal tissue block and stained with H&E. Stained sections were reviewed by center pathologist(s) who selected a colorectal cancer tumor block when possible, consisting of 70% to 80% tumor cells, and a block consisting of normal tissue for further sectioning. For planned immunohistochemistry and future protein-based studies, ten 4-μm or 5-μm paraffin sections from the tumor block were prepared and mounted unbaked on Probe-On Plus slides. For MSI testing and other future tumor DNA-based studies, ten 5-μm tumor sections were prepared and either mounted on glass slides or stored in microfuge tubes. When available, ten 5-μm normal tissue sections were similarly prepared and stored for DNA-based studies. DNA extractions from tumor and normal tissue for phase I recruitment was completed as part of the registry-wide MSI project, with remaining DNA stored at the local Colon CFR centers.

Confirmation of Colorectal Cancer Diagnoses. Confirmation of cancer diagnoses was sought for all reported colorectal cancers and, at some centers, for other reported invasive cancers. The level of confidence regarding a cancer diagnosis was classified into one of six categories (in decreasing order): (a) pathologist review of slides, (b) review of the pathology report; (c) cancer registry report or medical record(s) indicating treatment for the specific type of cancer; (d) report on a death certificate; (e) self-report; and (f) report by a relative. Pathology reports for all probands' qualifying colorectal cancers were reviewed, and data, including site, stage, histology, grade, distant spread, nodular involvement, etc., were abstracted onto a standardized review form developed by the Pathology Working Group. All pathology reviews are entered into a database and submitted to the ISC.

Characterization of Colorectal Cancer Tumors. One of two distinct molecular pathways leading to colorectal carcinogenesis involves the MMR pathway (21). Because it became evident that research of nearly any type on colorectal cancer would require characterizing participants' tumors according to DNA MMR competency, a competitive supplement was obtained to fund the Colon CFR–wide collection of tumors and characterization by tumor MSI, the phenotypic indicator of MMR competence (21). MSI testing was done on all available phase I Colon CFR tumors using 10 markers: four mononucleotide markers (BAT25, BAT26, BAT40, BAT34C4), four dinucleotide markers (D5S346, D17S250, D18S55, D10197), and two complex markers (ACTC and MycL; ref. 22). In general, tumors were classified as microsatellite stable (0% of unstable loci), MSI-low (>0% to <30% of unstable loci), or MSI-high (≥30% of unstable loci); unequivocal results for at least four markers were required to establish and report MSI status. MSI was completed on all affected phase I probands and affected family members with tumors meeting testing criteria and, similarly, on a selected sample of phase II affected participants (clinic-based and minority participants).

Immunohistochemical staining, a simpler and less expensive test than MSI analysis, has proved to be a valid alternative approach to identify tumors with MMR (23). Thus, in addition to the MSI testing, we did immunohistochemistry on all obtained clinic-based probands and affected relative tumors and, at a minimum, microsatellite instable population-based tumors to establish the presence or absence of protein expression for MLH1, MSH2, and MSH6 (and, at some centers, PMS2), primary protein constituents of the MMR machinery. Staining was done on 4-μm to 5-μm thick formalin-fixed, paraffin-embedded tissue sections and was conducted at three centers: Mayo Clinic, University of Queensland, and Mount Sinai Hospital. Commercially available monoclonal antibodies were used with control sections in each staining run, and assessment was standardized with protocols used for that laboratory. Although, we did not use standardized antibodies in all sites, site-specific antibodies and technical details are reported by Lindor et al. (23).

Molecular characterization testing of selected phase I colorectal cancer enrollees was completed during phase II (Fig. 2). Briefly, mutation testing for MLH1, MSH2, and MSH6 via dHPLC was conducted at three Colon CFR Centers: CCO, Australasia, and USC. Furthermore, the detection of large genomic rearrangements by MLPA was conducted under the direction of Dr. Stephen Thibodeau at the Mayo Clinic and the evaluation of methylation status of hMLH1 gene promoter was completed under the direction of Dr. Peter Laird at USC.

Figure 2.

Colon CFR molecular characterization study schema. Scheme represents the minimum selection criteria. Some sites did immunohistochemistry on all population-based tumors instead of only MSI positive tumors. Molecular characterization testing: immunohistochemistry, methylation of MLH1, deletion and mutation testing for MLH1, MSH2, MSH6, and confirmatory sequencing.

Figure 2.

Colon CFR molecular characterization study schema. Scheme represents the minimum selection criteria. Some sites did immunohistochemistry on all population-based tumors instead of only MSI positive tumors. Molecular characterization testing: immunohistochemistry, methylation of MLH1, deletion and mutation testing for MLH1, MSH2, MSH6, and confirmatory sequencing.

Close modal

Follow-up

Follow-up activities in phase II have included active and passive follow-up of phase I enrollees (excluding unrelated controls). The active follow-up has been conducted 4 to 5 years after original enrollment and includes updating the family history, administering a follow-up epidemiologic and medical history questionnaire, and ascertaining and recruiting additional family members when indicated (e.g., new diagnosis of colorectal cancer) or when not previously feasible (e.g., were under age at time of family recruitment). Pathology materials (tumor blocks and diagnostic slides) are sought on all newly diagnosed colorectal cancers, as well as collection of pathology reports or other documents for verification, such as death certificates and medical records. Passive follow-up has allowed ascertainment of major end points (cancer diagnoses and death) by linkage to tumor registries and death indices. In addition, centers have used newsletters and other mailings to participants to maintain contact and a current address.

Enrollment

From 1998 to 2002 (phase I), the six Colon CFR centers enrolled a total of 10,366 families (including controls) into the Colon CFR (Table 3). These represented 5,111 population-based case families, 4,474 population- and spouse-based control families, 441 clinic-based families with an affected proband, and 145 clinic-based families with an unaffected proband. Since 2002 (phase II), the centers enrolled individuals under the age of 50 years; therefore, an additional 2,672 case families, 354 population-based, and 68 spouse control families have been recruited. Table 2 describes data collection by study phase and ascertainment method; Table 3 describes the probands in terms of sex, age at onset, race, family history, and tumor characteristics. Active follow-up has been completed on >15,700 phase enrollees. Dietary questionnaires have been completed by nearly 4,000 probands, 2,600 controls, and 11,000 family members.

Table 3.

Data and biospecimen collection by ascertainment source and participant type

Population-based ascertainment
Clinic-based ascertainment*
Total
Phase IPhase IIPhase IPhase IIPhases I and II
Colorectal cancer–affected proband      
    With epidemiology data§ 5,111 2,141 441 448 8,141 
    With blood or mouthwash sample 4,661 1,852 450 415 7,378 
    With tumor block 4,391 1,131 406 383 6,311 
Unaffected proband      
    With epidemiology data§ N/A N/A 145 83 228 
    With blood or mouthwash sample N/A N/A 142 117 259 
Colorectal cancer–affected relative      
    With epidemiology data§ 533 132 516 143 1,324 
    With blood or mouthwash sample 425 126 506 132 1,189 
    With tumor block 433 100 596 149 1,278 
Unaffected relative      
    With epidemiology data§ 12,332 2,923 3,273 1,288 19,816 
    With blood or mouthwash sample 5,913 2,539 3,053 1,233 12,738 
Population-based control      
    With epidemiology data§ 3,754 354 4,108 
    With blood or mouthwash sample 2,431 301 2,732 
Spouse control      
    With epidemiology data§ 720 68 195 983 
    With blood or mouthwash sample 688 70 200 958 
No. families with the following members all having blood in hand      
    Affected proband with one unaffected sibling 993 460 141 95 1,689 
    Affected proband with ≥2 unaffected siblings 629 302 185 92 1,208 
    Affected proband with one affected sibling 144 32 65 22 263 
    Affected proband with ≥2 affected siblings 12 15 32 
    Unaffected proband with one affected sibling 32 15 47 
    Unaffected proband with ≥2 affected siblings 13 13 
Population-based ascertainment
Clinic-based ascertainment*
Total
Phase IPhase IIPhase IPhase IIPhases I and II
Colorectal cancer–affected proband      
    With epidemiology data§ 5,111 2,141 441 448 8,141 
    With blood or mouthwash sample 4,661 1,852 450 415 7,378 
    With tumor block 4,391 1,131 406 383 6,311 
Unaffected proband      
    With epidemiology data§ N/A N/A 145 83 228 
    With blood or mouthwash sample N/A N/A 142 117 259 
Colorectal cancer–affected relative      
    With epidemiology data§ 533 132 516 143 1,324 
    With blood or mouthwash sample 425 126 506 132 1,189 
    With tumor block 433 100 596 149 1,278 
Unaffected relative      
    With epidemiology data§ 12,332 2,923 3,273 1,288 19,816 
    With blood or mouthwash sample 5,913 2,539 3,053 1,233 12,738 
Population-based control      
    With epidemiology data§ 3,754 354 4,108 
    With blood or mouthwash sample 2,431 301 2,732 
Spouse control      
    With epidemiology data§ 720 68 195 983 
    With blood or mouthwash sample 688 70 200 958 
No. families with the following members all having blood in hand      
    Affected proband with one unaffected sibling 993 460 141 95 1,689 
    Affected proband with ≥2 unaffected siblings 629 302 185 92 1,208 
    Affected proband with one affected sibling 144 32 65 22 263 
    Affected proband with ≥2 affected siblings 12 15 32 
    Unaffected proband with one affected sibling 32 15 47 
    Unaffected proband with ≥2 affected siblings 13 13 

NOTE: Represents recruitment and data collection through December 31, 2006.

*

Clinic-based ascertainment reports affected probands and unaffected probands combined.

Phase I recruitment (1998-2002).

Phase II recruitment (2002-2007).

§

Counts exclude participants that provided family history and/or biospecimens but did not complete the epidemiology questionnaire.

Proband and Family Characteristics

The Colon CFR contains subgroups of probands and families with specific characteristics representing a continuum of risk for colorectal cancer (Table 4). The relatively high portion of probands diagnosed at a younger age and/or with a positive first-degree family history reflects, in part, the sampling strategies used at the Colon CFR centers (excluding FHCRC wherein all cases with age of 20-74 years, regardless of family history, were enrolled during phase I). Thirty eight percent (3,706) of all probands were diagnosed under the age of 50 years. Twenty one percent (2,005) of probands had one first-degree relative with colorectal cancer, and 6% (597) reported two or more first-degree relatives with colorectal cancer. Based on these family reports, we identified 799 (8% of all probands) who met the Amsterdam I criteria (24).

Table 4.

Colon CFR proband characteristics by ascertainment source

Population based
Clinic-based affected
Clinic-based unaffected
Total
Phase I*Phase IIPhase I*Phase IIPhase I*Phase II
Sex        
    Male 3,043 1,182 230 282 52 30 4,819 
    Female 3,093 1,223 230 204 112 71 4,933 
Age at diagnosis        
    <30 y 32 68 34 21 N/A N/A 155 
    30-39 y 271 341 95 79 N/A N/A 786 
    40-49 y 942 1,470 192 161 N/A N/A 2,765 
    50-59 y 1,801 210 87 68 N/A N/A 2,166 
    60-69 y 2,143 186 34 81 N/A N/A 2,444 
    ≥70 y 947 130 18 76 N/A N/A 1,171 
Primary site        
    Colon (ICD-O: 18.0, 18.2-18.7) 3,698 1,178 232 211 N/A N/A 5,319 
    Rectum (ICD-O: 19.9, 20.9, 21.8) 1,965 750 127 119 N/A N/A 2,961 
    Colorectal (ICD-O: 18.8, 18.9, 26.0) 284 434 97 150 N/A N/A 965 
    Appendix (ICD-O: 18.1) 33 26 N/A N/A 64 
    Multiple sites (synchronous primaries) 156 17 N/A N/A 178 
Proband's FDR history of colorectal cancer        
    0 affected FDRs 4,570 2,017 187 343 15 18 7,150 
    1 affected FDR 1,288 336 166 99 71 45 2,005 
    ≥2 affected FDRs 278 52 107 44 78 38 597 
    Amsterdam-II 61 31 20 128 
    Amsterdam-I 267 79 202 89 101 61 799 
Race        
    American Indian/Alaska Native 57 30 93 
    Asian 279 310 600 
    Native Hawaiian or other Pacific islander 26 19 47 
    Black or African American 138 348 497 
    White 5,366 1,333 440 459 135 89 7,822 
    More than one race 100 228 342 
    Unknown or not reported 170 137 13 21 351 
Tumor MSI status (minimum of five markers required)        
    MSI-high (30-100% makers unstable) 536 98 34 N/A N/A 670 
    MSI-Low (1-29% unstable) 431 20 N/A N/A 460 
    Microsatellite stable (0% unstable) 2,668 21 167 25 N/A N/A 2,881 
Tumor MMR protein expression status (immunohistochemistry)§        
    MLH1 or MLH1/PMS2 loss 358 36 48 57 N/A N/A 499 
    MSH2 or MSH2/MSH6 loss 82 17 45 25 N/A N/A 169 
    MSH6-only loss 35 19 17 18 N/A N/A 89 
    PMS2-only loss 34 24 18 N/A N/A 84 
    Other pattern of immunohistochemistry loss N/A N/A 
    No loss 2,847 431 202 238 N/A N/A 3,718 
Population based
Clinic-based affected
Clinic-based unaffected
Total
Phase I*Phase IIPhase I*Phase IIPhase I*Phase II
Sex        
    Male 3,043 1,182 230 282 52 30 4,819 
    Female 3,093 1,223 230 204 112 71 4,933 
Age at diagnosis        
    <30 y 32 68 34 21 N/A N/A 155 
    30-39 y 271 341 95 79 N/A N/A 786 
    40-49 y 942 1,470 192 161 N/A N/A 2,765 
    50-59 y 1,801 210 87 68 N/A N/A 2,166 
    60-69 y 2,143 186 34 81 N/A N/A 2,444 
    ≥70 y 947 130 18 76 N/A N/A 1,171 
Primary site        
    Colon (ICD-O: 18.0, 18.2-18.7) 3,698 1,178 232 211 N/A N/A 5,319 
    Rectum (ICD-O: 19.9, 20.9, 21.8) 1,965 750 127 119 N/A N/A 2,961 
    Colorectal (ICD-O: 18.8, 18.9, 26.0) 284 434 97 150 N/A N/A 965 
    Appendix (ICD-O: 18.1) 33 26 N/A N/A 64 
    Multiple sites (synchronous primaries) 156 17 N/A N/A 178 
Proband's FDR history of colorectal cancer        
    0 affected FDRs 4,570 2,017 187 343 15 18 7,150 
    1 affected FDR 1,288 336 166 99 71 45 2,005 
    ≥2 affected FDRs 278 52 107 44 78 38 597 
    Amsterdam-II 61 31 20 128 
    Amsterdam-I 267 79 202 89 101 61 799 
Race        
    American Indian/Alaska Native 57 30 93 
    Asian 279 310 600 
    Native Hawaiian or other Pacific islander 26 19 47 
    Black or African American 138 348 497 
    White 5,366 1,333 440 459 135 89 7,822 
    More than one race 100 228 342 
    Unknown or not reported 170 137 13 21 351 
Tumor MSI status (minimum of five markers required)        
    MSI-high (30-100% makers unstable) 536 98 34 N/A N/A 670 
    MSI-Low (1-29% unstable) 431 20 N/A N/A 460 
    Microsatellite stable (0% unstable) 2,668 21 167 25 N/A N/A 2,881 
Tumor MMR protein expression status (immunohistochemistry)§        
    MLH1 or MLH1/PMS2 loss 358 36 48 57 N/A N/A 499 
    MSH2 or MSH2/MSH6 loss 82 17 45 25 N/A N/A 169 
    MSH6-only loss 35 19 17 18 N/A N/A 89 
    PMS2-only loss 34 24 18 N/A N/A 84 
    Other pattern of immunohistochemistry loss N/A N/A 
    No loss 2,847 431 202 238 N/A N/A 3,718 

NOTE: Represents recruitment and data collection through December 31, 2006.

Only incident probands recruited during the funding period (1998-2007) are reported. Additional cases (either cases that were not selected for full enrollment based on their family history or were prevalent cases) are excluded from this report.

*

Phase I recruitment (1998-2002).

Phase II recruitment (2002-2007).

Results reported only if a minimum of four markers had definitive results. See Fig. 2 for testing scheme.

§

Results reported only if a minimum of two proteins had definitive results. See Fig. 2 for minimum testing scheme. Some population-based sites stained all tumors, not just MSI+. Some sites did not stain for PMS2.

Characterization of Colon CFR Tumors

MSI Analysis. The prevalence of MSI in the Colon CFR is based on the evaluation of over 4,000 phases I and II affected probands with tumors adequate for testing (Table 4). Of these participants who had their MSI evaluated, 72% were stable (microsatellite stable), 11% showed low instability (>0% to <30% unstable markers), and 17% showed high instability (≥30% unstable markers). MSI status varied by ascertainment source: clinic-based probands were twice as likely to be MSI-high as population-based probands (34% versus 17%).

Immunohistochemistry Analysis. Immunohistochemistry was used to test for the absence of protein expression for hMSH2, hMLH1, and hMSH6 (and PMS2 at Mayo Clinic, Australasia, CCO, and FHCRC). Of the 4,588 phases I and II tumors tested, 19% showed loss of expression for one or more proteins. Specifically, 499 (11%) showed loss of expression of either MLH1 or MLH1 and PMS2, 169 (4%) showed loss of expression of either MSH2 or MSH2 and MSH6, 89 (2%) showed loss of expression of MSH6 only, and 84 (2%) showed loss of expression of PMS-2 (not all centers included PMS2 testing in their immunohistochemistry protocol). Protein loss depended on sampling frame, with clinic-based proband lesions having the highest proportion of MMR protein loss.

The Colon CFR represents a unique and valuable resource for a wide range of studies on the etiology and prevention of colorectal cancer. In an international collaborative environment, the world's largest collection of colorectal cancer families has been assembled, complete with epidemiologic data, biospecimens, and tumor tissues. A thorough search is being conducted for MMR mutations, epigenetic, environmental, and other causes for this common disease. Colon CFR participants reflect a continuum of risk that will be invaluable for the characterization of known genes, the identification of new genes, and the investigation of variants in pathways known to be involved in colorectal cancer. The results of such studies will be relevant to other cancer sites as well.

The Colon CFR has many strengths, including the extensive enrollment of affected cases, relatives, and controls which will permit a wide variety of classic and novel designs. Furthermore, the high quality biological data and existing characterization of all tumors for MSI and germline MMR gene mutations will enable the conduct of additional molecular studies. There are some limitations to the current registry design. First, differences in sampling frames and probabilities across Colon CFR centers (25) make summarizing registry data a whole challenge; varying sampling probabilities may be addressed analytically by incorporating individual proband weights (26). However, differences in population sampling (i.e., between clinic-based and population-based) may yield disparate estimates of penetrance (e.g., for major cancer susceptibility genes; ref. 27), and therefore, stratified analyses will be essential. Conversely, concordance of results will greatly strengthen inferences. Second, study centers vary with respect to control populations. The use of siblings, spouses, or unaffected population controls may yield different strengths of association with respect to genes, phenotypes, or other common exposures. These issues may be addressed by, first, comparing stratum-specific estimates based on similar control types, and second, in the absence of heterogeneity, summarizing across centers using all control types. Third, some of the study participants eligible for this study did not participate. Indeed, there is a great range of response proportions depending on the population and design. If participation depends on the presence of a gene (or genes) or phenotype, such as MSI, the prevalence of the gene in the population may have been under- or overestimated (28); furthermore, if participation depended jointly on exposure and disease status, our estimation of any association may be biased (29). It has been shown, however, that the assessment of gene-environment interactions in case-control studies is not subject to selection bias under the assumption that genotype does not influence participation conditional upon exposure and disease status (30). Fourth, not all subjects provided blood samples for genetic studies or tissue for MSI and other future studies. Because illness and family history may be factors in this loss, we may, again, have a study group that represents different genetic and phenotypic profiles than the true source population. Nevertheless, overall, the disparate designs and multiple study centers of the Colon CFR have yielded a range of risks that will support many research opportunities.

The resources collected and developed by the Colon CFR are available for use by the international scientific community. Investigators interested in pursuing collaborative research projects that use these resources are invited to submit applications for access to available data and biological materials. The first step in the application process is the submission of a “concept description,” a short form describing the proposed project and the types of resources being requested. After submitting a concept description, applicants develop a full application with the support of a scientific liaison assigned to their proposed project. The scientific liaison is an internal CFR investigator familiar with the available resources and the application process. Full applications are evaluated by the reviewing committees with careful consideration given to their scientific merit, overlap with ongoing CFR studies, and the effect of the proposed study on the inventory of biological materials. The Advisory Committee is responsible for the final approval or disapproval of applications for CFR resources. New concept descriptions are accepted through an on-line submission form hosted by the ISC. A detailed description of the application process and a link to the online submission form can be found at http://epi.grants.cancer.gov/CFR/research.html. After approval, study support is available through the ISC, as well as individual study sites, if required. Study reports should include Colon CFR authors as appropriate, based on qualifying contributions (31).

In summary, the Colon CFR is now the largest resource for multidisciplinary investigators to study colorectal cancer (Fig. 3). The worldwide nature and unique designs ensure that investigators will be able to study colorectal cancer as it occurs in many different populations. The Colon CFR resource is now of even greater research potential, with follow-up data on the original Colon CFR families, a sizable number of identified mutation carriers, new enrollment of minority populations, and easy access to quality biospecimens and molecular, epidemiologic, and pathology data from all centers. Colon CFR investigators have already participated in numerous projects with external researchers from throughout the world and have initiated Colon CFR projects that include new collaborators, including young investigators. This rich resource will be available to the international community of scientists interested in studying colorectal cancer for many years to come.

Figure 3.

Overview of Colon CFR resource.

Figure 3.

Overview of Colon CFR resource.

Close modal

Grant support: NIH National Cancer Institute grants RFA CA-95-011, UO1 CA097735 (Australian Colorectal Cancer Family Registry), UO1 CA074799 (USC Familial Colorectal Neoplasia Collaborative Group), UO1 CA074800 (Mayo Clinic Cooperative Family Registry for Colon Cancer Studies), UO1 CA074783 (Ontario Registry for Studies of Familial Colorectal Cancer), UO1 CA074794 (Seattle Colorectal Cancer Family Registry), UO1 CA074806 (University of Hawaii Colorectal Cancer Family Registry), and UO1 CA078296 (University of California, Irvine Informatics Center).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1
Zhao LP, Hsu L, Davidov O, Potter J, Elston RC, Prentice RL. Population-based family study designs: an interdisciplinary research framework for genetic epidemiology.
Genet Epidemiol
1997
;
14
:
365
–88.
2
Lynch HT, Lynch JF. Familial factors and genetic predisposition to cancer: population studies.
Cancer Detect Prev
1991
;
15
:
49
–57.
3
Warthin AS. Heredity with reference to carcinoma.
Arch Int Med
1913
;
12
:
546
–55.
4
Lynch PM, Lynch HT. Colon cancer genetics. New York: Van Nostrand Rheinhold; 1985.
5
Veale AMO. Intestinal polyposis. Cambridge: Cambridge University Press; 1965.
6
Peltomaki P, Vasen HF; The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer. Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study.
Gastroenterology
1997
;
113
:
1146
–58.
7
Reya T, Clevers H. Wnt signalling in stem cells and cancer.
Nature
2005
;
434
:
843
–50.
8
Leppert M, Dobbs M, Scambler P, et al. The gene for familial polyposis coli maps to the long arm of chromosome 5.
Science
1987
;
238
:
1411
–3.
9
Bodmer WF, Bailey CJ, Bodmer J, et al. Localization of the gene for familial adenomatous polyposis on chromosome 5.
Nature
1987
;
328
:
614
–6.
10
Groden J, Thliveris A, Samowitz W, et al. Identification and characterization of the familial adenomatous polyposis coli gene.
Cell
1991
;
66
:
589
–600.
11
Powell SM, Zilz N, Beazer-Barclay Y, et al. APC mutations occur early during colorectal tumorigenesis.
Nature
1992
;
359
:
235
–7.
12
Kane MF, Loda M, Gaida GM, et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines.
Cancer Res
1997
;
57
:
808
–11.
13
Herman JG, Umar A, Polyak K, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma.
Proc Natl Acad Sci U S A
1998
;
95
:
6870
–5.
14
Potter JD. Colorectal cancer: molecules and populations.
J Natl Cancer Inst
1999
;
91
:
916
–32.
15
John EM, Hopper JL, Beck JC, et al. The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer.
Breast Cancer Res
2004
;
6
:
R375
–89.
16
Stram DO, Hankin JH, Wilkens LR, et al. Calibration of the dietary questionnaire for a multiethnic cohort in Hawaii and Los Angeles.
Am J Epidemiol
2000
;
151
:
358
–70.
17
Giles GG, English DR. The Melbourne Collaborative Cohort Study.
IARC Sci Publ
2002
;
156
:
69
–70.
18
Lum A, LeMarchand LL. A simple mouthwash method for obtaining genomic DNA in molecular epidemiological studies.
Cancer Epidemiol Biomarkers Prev
1998
;
7
:
719
–24.
19
Garcia-Closas M, Egan KM, Abruzzo J, et al. Collection of genomic DNA from adults in epidemiological studies by buccal cytobrush and mouthwash.
Cancer Epidemiol Biomarkers Prev
2001
;
10
:
687
–96.
20
Miller G. Immortalization of human lymphocytes by Epstein-Barr virus.
Yale J Biol Med
1982
;
55
:
305
–10.
21
Loeb LA. Microsatellite instability: marker of a mutator phenotype in cancer.
Cancer Res
1994
;
54
:
5059
–63.
22
Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer.
Cancer Res
1998
;
58
:
5248
–57.
23
Lindor NM, Burgart LJ, Leontovich O, et al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors.
J Clin Oncol
2002
;
20
:
1043
–8.
24
Vasen HF, Mecklin JP, Khan PM, Lynch HT. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC).
Dis Colon Rectum
1991
;
34
:
424
–5.
25
Seminara D, editor. Innovative study designs and analytic approaches to the genetic epidemiology of cancer.
J Natl Cancer Inst Monogr
1999
;
26
:
1
–105.
26
Lohr SL. Sampling: Design and Analysis. Pacific Grove: Brooks/Cole; 1998.
27
Gong G, Whittemore A. Optimal designs for estimating penetrance of rare mutations of a disease-susceptibility gene.
Genet Epidemiol
2003
;
24
:
173
–80.
28
Garcia-Closas M, Thompson WD, Robins JM. Differential misclassification and the assessment of gene-environment interactions in case-control studies.
Am J Epidemiol
1998
;
147
:
426
–33.
29
Rothman KJ, Greenland S. Modern Epidemiology. 2nd ed. Philadelphia: Lippincott-Raven Publishers; 1998.
30
Morimoto LM, White E, Newcomb PA. Selection bias in the assessment of gene-environment interaction in case-control studies.
Am J Epidemiol
2003
;
158
:
259
–63.
31
International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals.
Ann Intern Med
1988
;
108
:
258
–65.